OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2
Julia Velez, Brandon Dale, Kwang‐Su Park, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116154-116154
Closed Access | Times Cited: 12
Julia Velez, Brandon Dale, Kwang‐Su Park, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116154-116154
Closed Access | Times Cited: 12
Showing 12 citing articles:
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities
Michał Woźniak, Małgorzata Czyż
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Michał Woźniak, Małgorzata Czyż
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Research progress and applications of epigenetic biomarkers in cancer
Jianjun Gao, Wujiang Shi, Jiangang Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Jianjun Gao, Wujiang Shi, Jiangang Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research
Mariona Pont, Marta Marqués, Anabel Sorolla
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13518-13518
Open Access | Times Cited: 2
Mariona Pont, Marta Marqués, Anabel Sorolla
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13518-13518
Open Access | Times Cited: 2
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Varadha Balaji Venkadakrishnan, Adam G. Presser, Richa Singh, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Recent Developments and Evolving Therapeutic Strategies in KMT2A ‐Rearranged Acute Leukemia
Lei Yin, Lin Wan, Youjian Zhang, et al.
Cancer Medicine (2024) Vol. 13, Iss. 20
Open Access | Times Cited: 1
Lei Yin, Lin Wan, Youjian Zhang, et al.
Cancer Medicine (2024) Vol. 13, Iss. 20
Open Access | Times Cited: 1
Targeting chromatin modifying complexes in acute myeloid leukemia
Alexandra Schurer, Shira Glushakow-Smith, Kira Gritsman
Stem Cells Translational Medicine (2024)
Open Access | Times Cited: 1
Alexandra Schurer, Shira Glushakow-Smith, Kira Gritsman
Stem Cells Translational Medicine (2024)
Open Access | Times Cited: 1
Salicylaldehyde derived piperazine functionalized hydrazone ligand-based Pt(II) complexes: Inhibition of EZH2-dependent tumorigenesis in pancreatic ductal adenocarcinoma, synergism with PARP inhibitors and enhanced apoptosis
Zhimin Lv, Amjad Ali, Cheng Zou, et al.
Dalton Transactions (2024) Vol. 53, Iss. 33, pp. 13871-13889
Closed Access
Zhimin Lv, Amjad Ali, Cheng Zou, et al.
Dalton Transactions (2024) Vol. 53, Iss. 33, pp. 13871-13889
Closed Access
The epigenetic role of EZH2 in acute myeloid leukemia
Jinyong Fang, Jingcheng Zhang, Lujian Zhu, et al.
PeerJ (2024) Vol. 12, pp. e18656-e18656
Open Access
Jinyong Fang, Jingcheng Zhang, Lujian Zhu, et al.
PeerJ (2024) Vol. 12, pp. e18656-e18656
Open Access
Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway
Mingwei Fu, Yuanjiang Wang, Min Ge, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 113, pp. 129968-129968
Closed Access
Mingwei Fu, Yuanjiang Wang, Min Ge, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 113, pp. 129968-129968
Closed Access
